MULTI EXPRESS DEFENDER VONCERT - ELI LILLY & CO/BAYER/NOVO-NORDISK B/PFIZER INC MULTI EXPRESS DEFENDER VONCERT - ELI LILLY & CO/BAYER/NOVO-NORDISK B/PFIZER INC Stock
Certificat
F43058
DE000VM75109
| Market Closed - Borsa Italiana 11:44:59 2024-06-28 EDT | ||
| 91 EUR | +1.00% |
|
| Current month | -0.87% | ||
| 1 month | +0.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 91 | +1.00% |
| 24-06-27 | 90.1 | 0.00% |
| 24-06-26 | 90.1 | -0.55% |
| 24-06-25 | 90.6 | -0.55% |
| 24-06-24 | 91.1 | +1.17% |
Real-time Borsa Italiana
Last update June 28, 2024 at 11:44 am
More quotesStatic data
| Product type | Certificats Divers |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| F43058 | |
| ISIN | DE000VM75109 |
| Date issued | 2024-01-10 |
| Maturity | 2027-01-08 (922 Days) |
| Parity | 1 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 99.3 € |
|---|---|
| Lowest since issue | 83.35 € |
| Spread | 1 € |
| Spread % | 1.09% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- F43058 Certificat
